Leukemia risk after adjuvant treatment of early breast cancer

Author： Balduzzi Alessandra   Castiglione-Gertsch Monica  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.1, Iss.1, 2005-07, pp. : 73-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant Endocrine Treatment in Premenopausal Early Breast Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 9-13

Karger

Access to resources Recommend Favorite

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer

By Buzdar Aman   Chlebowski Rowan   Cuzick Jack   Duffy Sean   Forbes John   Jonat Walter   Ravdin Peter    

Current Medical Research and Opinion, Vol. 22, Iss. 8, 2006-08 ,pp. : 1575-1585

Informa Healthcare

Access to resources Recommend Favorite

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer

By Ligibel Jennifer A   Winer Eric P  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 89-97

Future Medicine

Access to resources Recommend Favorite

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 14-17

Karger

Access to resources Recommend Favorite